ASCO Abstracts Released: MRD, CGP & MCED In Focus

Research evidence excerpt

ASCO Abstracts Released: MRD, CGP & MCED In Focus

TD SECURITIES (USA) LLC QUICK TAKE: INDUSTRY UPDATE

May 22, 2026

■Life Science & Diagnostic Tools: ASCO Abstracts Released: MRD, CGP & MCED

Diagnostics In Focus

Dan Brennan, CFA THE TD COWEN INSIGHT

646 562 1317

ASCO released abstract information at 5PM Thurs (late-breaker details come day of

dan.brennan@tdsecurities.com

presentation). We expect additional info to be revealed at ASCO. While we don't view any

Kyle Boucher abstract to be a material stock event, in total abstracts should support future MRD filings, CGP

617 946 3735 data can enhance competitive profiles, and early MCED data provides early RWE insight. We'll

kyle.boucher@tdsecurities.com

seek diligence w/ mgmts & oncologists.

William Ruby

646 562 1325 ASCO Abstract Data Released - Highlights Across our Coverage

william.ruby@tdsecurities.com

ASCO abstracts were released Thursday evening; last month we highlighted a number of

Pradeep Ambrose, Ph.D. abstract titles of note across our coverage (link), with the full release of details now available.

646 562 1378

Below we review the data and insights from a number of abstracts that were released and

pradeep.ambrose@tdsecurities.com

initial thoughts across much of our Dx coverage (CAI, GH, GRAL, MYGN, NEO, NTRA, PSNL,

TEM).

Key Highlights Across Our Dx Coverage

NTRA presented 35 studies at ASCO and highlighted several in a press release (link) primarily

focused on MRD, including multiple analyses from the GALAXY study in CRC, Pan-Cancer MRD

data, and abstracts on NTRA's Phased Variant technology from the Foresight acquisition.

For GALAXY/CRC, an interim analysis showed that CRC patients who were converted from

Signatera negative (at 4 weeks post surgery) to positive at 12 weeks saw benefit from adjuvant